CUE · Cue Biopharma Inc. Common Stock
View on chartInsiders & Stakes
| Aaron G.L. Fletcher Director | ▲ Buy | Open Market | 940,000 Shares held | 5/24/2022 | View profile |
| Lin Shao-Lee CHIEF EXECUTIVE OFFICER | ▼ Sell | Open Market | 705,995 Shares held | 8/13/2026 | View profile |
| Gray Cameron Director | ▼ Sell | Tax Withholding | 687,049 Shares held | 6/14/2022 | View profile |
| PASSERI DANIEL R CHIEF EXECUTIVE OFFICER | ▲ Buy | Open Market | 164,578 Shares held | 12/16/2024 | View profile |
| Suri Anish PRESIDENT AND CSO | ▲ Buy | Open Market | 135,638 Shares held | 8/25/2023 | View profile |
| Ray Sumita Chief Legal Compliance Officer | ▼ Sell | Open Market | 118,545 Shares held | 8/13/2026 | View profile |
| Meluzio Michael Vincent VP, Prin. Accounting Officer | ▼ Sell | Open Market | 48,961 Shares held | 8/13/2026 | View profile |
| Sarraf Pasha | ▲ Buy | Grant | 32,595 Shares held | 7/9/2026 | View profile |
| Borie Dominique Christian Chief Medical Officer | ▲ Buy | Grant | 31,500 Shares held | 7/13/2026 | View profile |
| Morich Frank Director | ▲ Buy | Open Market | 28,000 Shares held | 5/27/2022 | View profile |
| Ahlers James M Chief Financial Officer | ▲ Buy | Grant | 25,500 Shares held | 7/30/2026 | View profile |
| Garzone Pamela | ▲ Buy | Grant | 21,800 Shares held | 7/9/2026 | View profile |
| Camardo Daniel A. | ▲ Buy | Grant | 21,800 Shares held | 7/9/2026 | View profile |
| Meehan Viola Mong | ▲ Buy | Grant | 21,800 Shares held | 7/9/2026 | View profile |
| Millar Kerri-Ann CHIEF FINANCIAL OFFICER | ▼ Sell | Tax Withholding | 14,311 Shares held | 8/22/2022 | View profile |
| Kiener Peter A Director | ▼ Sell | Open Market | 357 Shares held | 3/23/2023 | View profile |
Transaction History
| Meluzio Michael Vincent | ▲ Buy | Option Exercise | 13,647 | $0 | 8/13/2026 |
| Meluzio Michael Vincent | ▼ Sell | Open Market | 1,519 | $45K | 8/13/2026 |
| Meluzio Michael Vincent | ▼ Sell | Open Market | 4,106 | $125K | 8/13/2026 |
| Meluzio Michael Vincent | ▼ Sell | Open Market | 3 | $93 | 8/13/2026 |
| Lin Shao-Lee | ▼ Sell | Open Market | 5,423 | $147K | 8/13/2026 |
| Lin Shao-Lee | ▼ Sell | Open Market | 2,375 | $67K | 8/13/2026 |
| Lin Shao-Lee | ▼ Sell | Open Market | 10,460 | $308K | 8/13/2026 |
| Ray Sumita | ▲ Buy | Option Exercise | 18,196 | $0 | 8/13/2026 |
| Ray Sumita | ▼ Sell | Open Market | 2,383 | $70K | 8/13/2026 |
| Ray Sumita | ▼ Sell | Open Market | 6,442 | $196K | 8/13/2026 |
| Ray Sumita | ▼ Sell | Open Market | 4 | $125 | 8/13/2026 |
| Lin Shao-Lee | ▲ Buy | Option Exercise | 109,179 | $0 | 8/12/2026 |
| Lin Shao-Lee | ▼ Sell | Open Market | 34,225 | $924K | 8/12/2026 |
| Lin Shao-Lee | ▼ Sell | Open Market | 5,775 | $160K | 8/12/2026 |
| Ahlers James M | ▲ Buy | Grant | 25,500 | $0 | 7/30/2026 |
| Borie Dominique Christian | ▲ Buy | Grant | 31,500 | $0 | 7/13/2026 |
| Garzone Pamela | ▲ Buy | Grant | 21,800 | $0 | 7/9/2026 |
| Camardo Daniel A. | ▲ Buy | Grant | 21,800 | $0 | 7/9/2026 |
| Sarraf Pasha | ▲ Buy | Grant | 21,800 | $0 | 7/9/2026 |
| Meehan Viola Mong | ▲ Buy | Grant | 21,800 | $0 | 7/9/2026 |
| Meluzio Michael Vincent | ▲ Buy | Grant | 40,942 | $0 | 7/9/2026 |
| Ray Sumita | ▲ Buy | Grant | 54,589 | $0 | 7/9/2026 |
| Lin Shao-Lee | ▲ Buy | Grant | 327,537 | $0 | 7/9/2026 |
| Lin Shao-Lee | ▲ Buy | Grant | 327,537 | $0 | 5/3/2026 |
| Sarraf Pasha | ▲ Buy | Open Market | 4,229 | $1K | 12/30/2025 |
| Sarraf Pasha | ▲ Buy | Open Market | 77,148 | $23K | 12/30/2025 |
| Sarraf Pasha | ▲ Buy | Open Market | 86,947 | $28K | 12/30/2025 |
| Sarraf Pasha | ▲ Buy | Open Market | 78,116 | $24K | 12/30/2025 |
| Sarraf Pasha | ▲ Buy | Open Market | 77,417 | $23K | 12/30/2025 |
| PASSERI DANIEL R | ▲ Buy | Open Market | 30,000 | $31K | 12/16/2024 |
| Suri Anish | ▲ Buy | Open Market | 4,000 | $11K | 8/25/2023 |
| PASSERI DANIEL R | ▲ Buy | Open Market | 3,000 | $9K | 8/14/2023 |
| Kiener Peter A | ▲ Buy | Option Exercise | 9,682 | $28K | 3/23/2023 |
| Kiener Peter A | ▼ Sell | Open Market | 9,325 | $31K | 3/23/2023 |
| Millar Kerri-Ann | ▼ Sell | Tax Withholding | 2,828 | $9K | 8/22/2022 |
| Millar Kerri-Ann | ▲ Buy | Option Exercise | 6,667 | — | 8/21/2022 |
| Gray Cameron | ▼ Sell | Other | 61,111 | $165K | 6/14/2022 |
| Gray Cameron | ▼ Sell | Tax Withholding | 51,562 | $165K | 6/14/2022 |
| Morich Frank | ▲ Buy | Open Market | 28,000 | $105K | 5/27/2022 |
| Aaron G.L. Fletcher | ▲ Buy | Open Market | 55,000 | $184K | 5/24/2022 |
| Aaron G.L. Fletcher | ▲ Buy | Open Market | 150,000 | $528K | 5/23/2022 |
| Suri Anish | ▲ Buy | Option Exercise | 16,668 | — | 3/31/2022 |
| Suri Anish | ▼ Sell | Tax Withholding | 7,068 | $34K | 3/31/2022 |
| PASSERI DANIEL R | ▲ Buy | Option Exercise | 75,000 | — | 3/31/2022 |
| PASSERI DANIEL R | ▼ Sell | Tax Withholding | 32,122 | $157K | 3/31/2022 |
| PASSERI DANIEL R | ▼ Sell | Gift | 10,000 | $0 | 3/31/2022 |
| Aaron G.L. Fletcher | ▲ Buy | Open Market | 735,000 | $3.5M | 3/31/2022 |
| Kiener Peter A | ▲ Buy | Option Exercise | 1,361 | $4K | 11/16/2021 |
| Kiener Peter A | ▼ Sell | Open Market | 1,361 | $25K | 11/16/2021 |
| Kiener Peter A | ▲ Buy | Option Exercise | 18,815 | $54K | 11/15/2021 |
| Kiener Peter A | ▼ Sell | Open Market | 18,815 | $337K | 11/15/2021 |
| Suri Anish | ▲ Buy | Option Exercise | 8,000 | $66K | 11/15/2021 |
| Suri Anish | ▼ Sell | Open Market | 8,000 | $144K | 11/15/2021 |
| Suri Anish | ▲ Buy | Option Exercise | 20,000 | $128K | 11/11/2021 |
| Suri Anish | ▼ Sell | Open Market | 20,000 | $301K | 11/11/2021 |
| Suri Anish | ▼ Sell | Tax Withholding | 14,134 | $183K | 10/6/2021 |
| Suri Anish | ▲ Buy | Option Exercise | 33,334 | — | 10/3/2021 |
| Millar Kerri-Ann | ▲ Buy | Option Exercise | 1,251 | $9K | 10/1/2021 |
| Millar Kerri-Ann | ▼ Sell | Open Market | 1,251 | $18K | 10/1/2021 |
| PASSERI DANIEL R | ▲ Buy | Option Exercise | 75,000 | — | 9/30/2021 |
| PASSERI DANIEL R | ▼ Sell | Tax Withholding | 31,677 | $462K | 9/30/2021 |
| PASSERI DANIEL R | ▲ Buy | Open Market | 3,400 | $50K | 9/24/2021 |
| Suri Anish | ▲ Buy | Option Exercise | 20,000 | $128K | 9/23/2021 |
| Suri Anish | ▼ Sell | Open Market | 20,000 | $305K | 9/23/2021 |
| Millar Kerri-Ann | ▲ Buy | Option Exercise | 6,667 | $0 | 8/23/2021 |
| Millar Kerri-Ann | ▼ Sell | Tax Withholding | 1,961 | $0 | 8/23/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Cue Biopharma CUE-221 Meets Phase II Goals for Hives
Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.
Cue Biopharma CUE-221 Meets Phase II Goals for Hives. Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.